Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Exosome Therapy for Chronic Wound Healing.

Basamage L., Ahn HJ., Choi HS., Antonio CR., Alarcão AL., Silva SN.

Laboratory Study on Chronic Wound, Immune Modulation, published in Plast Reconstr Surg Glob Open (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Plast Reconstr Surg Glob Open (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41050971
DOI
10.1097/GOX.0000000000007200

Abstract (original English)

Chronic lower-extremity ulcers linked to diabetes, venous insufficiency, or smoking are difficult to heal because of impaired vascularity, persistent inflammation, and extracellular matrix dysfunction. Exosome therapy-a cell-free regenerative approach-may address these deficits by delivering proangiogenic and immunomodulatory cargo. We evaluated its clinical usage in a case series. Four adults (age 42-62 y) with ulcers present for 6 months or more and refractory to compression, debridement, and topical care received monthly topical applications of adipose-derived stem-cell exosomes (Exo-HL, Primoris International Co., Ltd., Seoul, Korea), 1 × 10 12 particles/mL; 0.1 mL/cm 2 wound area). Wounds were photographed and measured every 2-4 weeks; Doppler ultrasonography quantified arterial resistive index and venous reflux at baseline and 3-month intervals. Follow-up continued for up to 7 months. Median baseline ulcer area was 12.4 cm² (range, 4.8-26.1 cm²). All wounds showed visible granulation within 2 weeks; 3 achieved complete closure after a median of 94 days (range, 60-180 d). Mean arterial resistive index decreased from 0.93 ± 0.04 to 0.77 ± 0.03, and venous reflux time fell from 2.8 ± 0.3 to 1.4 ± 0.2 seconds. No adverse events or wound infections occurred. Exosome therapy was well tolerated and associated with rapid granulation, improved perfusion, and durable closure of ref

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research